Biomatics Capital Partners

VCMatch tracks Biomatics Capital Partners as an investor focused on Biotech, Medtech, and Digital Health companies, Pre-Seed and Seed rounds, and $94.4m to $120m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$94.4m to $120m

Stages

Pre-Seed, Seed, Series A, Series B, Late Stage

Focus Areas

Biotech, Medtech, Digital Health

Geography

Not specified

Investment Thesis

Biomatics invests at the convergence of genomics and digital data to build the next generation of companies that transform medicine into a value-based healthcare system. They pair deep scientific insight (from gene editing to DNA synthesis) with hands-on business execution, acting as active partners who advise, board-seat and deploy their network to scale early-stage breakthrough science into therapeutics, diagnostics and new delivery models (aiming for “lower costs and better patient outcomes”).

Is Biomatics Capital Partners right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Biomatics Capital Partners is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Medtech, Digital Health, and Pharma, with public check-size signals around $94.4m to $120m.

Focus statement

Biomatics focuses on companies at the intersection of genomics and digital data — including gene editing, DNA synthesis, diagnostics, precision therapeutics and novel delivery models — with the goal of enabling value-based healthcare. As the site states: “Biomatics helps create the next generation of companies that will lead this transformation.”

Value Add

Scientific + clinical founder-level expertise: led by Dr. Boris Nikolic (M.D., postdoc at Harvard Medical School) with deep academic and company-building experience.
Hands-on, active investor approach: takes board seats/board observer roles and “took an active role” guiding portfolio companies (e.g., Editas) from early-stage to IPO.
Track record of leading large, landmark financings: e.g., “leading a $120 million Series B round, marking the largest financial investment to a CRISPR startup.”
Focus on the full genomics stack: explicit coverage “from gene editing to DNA synthesis” and investments spanning therapeutics, diagnostics, and delivery models.
Network-driven value creation: emphasizes advising and “creating a vital network of experts to truly create exceptional value.”
Nimble, visionary team that combines passion for groundbreaking technologies with business acumen to support entrepreneurs through risky, frontier areas.